Anbio Biotechnology (NNNN) Accumulated Expenses (2023 - 2025)

Anbio Biotechnology (NNNN) has 3 years of Accumulated Expenses data on file, last reported at $87836.0 in Q4 2025.

• On a quarterly basis, Accumulated Expenses fell 16.33% year-over-year to $87836.0 in Q4 2025; TTM through Dec 2025 was $87836.0, a 16.33% decrease from a year earlier, with the FY2025 full-year figure at $87836.0, down 16.33% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $87836.0, down from $104979.0 in the prior quarter.
• Over the last five years, Accumulated Expenses for NNNN reached as high as $130967.0 in Q4 2023 and fell as low as $87836.0 in Q4 2025.
• Historically, Accumulated Expenses has averaged $107927.3 across 3 years, with a median of $104979.0 in 2024.
• Across the five-year window, Accumulated Expenses decreased 19.84% in 2024 and declined 16.33% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $130967.0 in 2023, then slipped by 19.84% to $104979.0 in 2024, then decreased by 16.33% to $87836.0 in 2025.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $87836.0 in Q4 2025, $104979.0 in Q4 2024, and $130967.0 in Q4 2023.